Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for Post-Treatment Lyme Disease
NCT05305105Phase 1Completed
- Sponsor
- Johns Hopkins University
- Start
- Jul 2022
- Primary completion
- Oct 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of psilocybin in post-treatment Lyme disease syndrome (PTLDS), sponsored by Johns Hopkins University. Primary endpoints: General Symptom Questionnaire-30 and Short Form-36. Started Jul 2022; status: completed.
02
Drugs
psilocybin
03
Conditions
post-treatment Lyme disease syndrome (PTLDS)
Beyond the preview
Go deeper on NCT05305105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05305105.